The American Journal of Managed Care

Flotufolastat F 18 Injection for Prostate Cancer Added to NCCN Guidelines

Data from 2 studies, LIGHTHOUSE and SPOTLIGHT, have shown the benefit of flotufolastat F 18 injection as a radiohybrid PSMA-targeted PET imaging agent in prostate cancer. The agent has now been added ...
Healio

FDA approves new formulation of PET imaging agent for prostate cancer

The FDA has approved a new formulation of an F 18 prostate-specific membrane antigen imaging agent for men with prostate cancer, according to an industry press release. As Healio previously reported, ...
Business Wire

Blue Earth Diagnostics Announces Reader Reproducibility Results from Phase 3 LIGHTHOUSE Trial of POSLUMA® (Flotufolastat F 18) Injection in Newly Diagnosed Prostate Cancer

− Oral presentation highlighted at 2023 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting – MONROE TOWNSHIP, N.J. & OXFORD, England--(BUSINESS WIRE)--Blue Earth Diagnostics, a ...
Business Wire

Blue Earth Diagnostics Announces Addition of POSLUMA® (Flotufolastat F 18) Injection to NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer

MONROE TOWNSHIP, NJ, & OXFORD, England--(BUSINESS WIRE)--Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, ...
Morningstar

First Patients in the UK Receive Doses of Blue Earth Therapeutics' Investigational Radiopharmaceutical Therapy Lutetium (177Lu) rhPSMA-10.1 Injection for Metastatic Castrate ...

St Bartholomew's Hospital and The James Cook University Hospital mark key UK expansion of the company's Phase 2 mCRPC programme Dr Kenrick Ng, Medical Oncology Consultant, St Bartholomew's Hospital, ...